Literature DB >> 10442906

Risk factors for radiation maculopathy and papillopathy after intraocular irradiation.

E S Gragoudas1, W Li, A M Lane, J Munzenrider, K M Egan.   

Abstract

PURPOSE: To evaluate rates of occurrence and risk factors for radiation maculopathy and radiation papillopathy in patients with choroidal melanoma at high risk for these complications.
DESIGN: Cohort study. PARTICIPANTS: A total of 558 patients treated with proton irradiation for choroidal melanoma between 1986 and 1996 with small to moderate sized tumors (less than 5 mm in height and 15 mm in diameter) located within 4 disc diameters of the macula or optic nerve and with a median ocular follow-up of 4 years.
METHODS: Annual and cumulative rates of each endpoint were estimated using life table approaches. Prognostic factors were evaluated using the Cox proportional hazards regression. MAIN OUTCOME MEASURES: Radiation maculopathy, radiation papillopathy, and vision loss to worse than 20/100.
RESULTS: Cumulative 5-year rates for radiation maculopathy, radiation papillopathy, and vision loss were 64%, 35%, and 68%, respectively. Complication rates rose as a function of radiation exposure to the macula (P for trend = 0.04) or optic disc (P for trend < 0.001), although dose-response patterns were nonlinear. History of diabetes was a significant risk factor for maculopathy (P < 0.001) and optic neuropathy (P = 0.009).
CONCLUSIONS: The onset of radiation vasculopathy is determined primarily by the degree of irradiation exposure to the macula and optic disc. Risk may be enhanced among those with underlying vascular disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10442906     DOI: 10.1016/S0161-6420(99)90455-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  33 in total

1.  Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height.

Authors:  Ilkka Puusaari; Bertil Damato; Tero Kivelä
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

2.  Long-term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis).

Authors:  James L Kinyoun
Journal:  Trans Am Ophthalmol Soc       Date:  2008

3.  Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma.

Authors:  Ivana K Kim; Anne Marie Lane; Purva Jain; Caroline Awh; Evangelos S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

4.  Risk factors for radiation-induced optic neuropathy: a case-control study.

Authors:  Ian Ferguson; Julie Huecker; Jiayi Huang; Collin McClelland; Gregory Van Stavern
Journal:  Clin Exp Ophthalmol       Date:  2017-03-09       Impact factor: 4.207

5.  Manganese-enhanced MRI of human choroidal melanoma xenografts.

Authors:  Rod D Braun; Marius Gradianu; Kerry S Vistisen; Robin L Roberts; Bruce A Berkowitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-03       Impact factor: 4.799

6.  Longstanding symptomatic choroidal hemangioma managed with limited PDT as initial or salvage therapy.

Authors:  F D Verbraak; R O Schlingemann; J E E Keunen; M D de Smet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-18       Impact factor: 3.117

7.  Enucleation for haemophthalmus secondary to choroidal neovascularisation in polypoidal choroidal vasculopathy: a therapeutic and diagnostic dilemma.

Authors:  Noor Aniah Azmi; Amin Ahem; Mushawiahti Mustapha; Mae-Lynn Catherine Bastion
Journal:  BMJ Case Rep       Date:  2016-09-28

8.  Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience.

Authors:  Y M Bartlema; J A Oosterhuis; J G Journée-De Korver; R E Tjho-Heslinga; J E E Keunen
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

9.  [Endoresection following proton beam irradiation of large uveal melanomas].

Authors:  N E Bechrakis; S Höcht; P Martus; K M Kreusel; J Heese; M H Foerster
Journal:  Ophthalmologe       Date:  2004-04       Impact factor: 1.059

10.  I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30.

Authors:  H Culver Boldt; B Michele Melia; Judy C Liu; Sandra M Reynolds
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.